Mary Browning

609 total citations
17 papers, 461 citations indexed

About

Mary Browning is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Mary Browning has authored 17 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Mary Browning's work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Mary Browning is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Mary Browning collaborates with scholars based in United States and United Kingdom. Mary Browning's co-authors include William G. Wierda, Alessandra Ferrajoli, Michael J. Keating, Susan O’Brien, Hagop M. Kantarjian, Susan Lerner, Jörge E. Cortes, Stefan Faderl, Deborah A. Thomas and Charles Koller and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mary Browning

16 papers receiving 445 citations

Peers

Mary Browning
Mt Fierro Italy
Amy Goodrich United States
R. F. Bezares Argentina
S Cardona Italy
A. Lakhani United Kingdom
P Travade France
K. R. United States
Jay Schachner United States
M. P. A. Lyttelton United Kingdom
M. Hidajat Belgium
Mt Fierro Italy
Mary Browning
Citations per year, relative to Mary Browning Mary Browning (= 1×) peers Mt Fierro

Countries citing papers authored by Mary Browning

Since Specialization
Citations

This map shows the geographic impact of Mary Browning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Browning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Browning more than expected).

Fields of papers citing papers by Mary Browning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Browning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Browning. The network helps show where Mary Browning may publish in the future.

Co-authorship network of co-authors of Mary Browning

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Browning. A scholar is included among the top collaborators of Mary Browning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Browning. Mary Browning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Browning, Mary, et al.. (2013). Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and Young Adults. Journal of Pediatric Oncology Nursing. 30(2). 63–77. 29 indexed citations
2.
Wierda, William G., Thomas J. Kipps, Michael J. Keating, et al.. (2010). Self‐administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 117(1). 116–124. 18 indexed citations
3.
Browning, Mary, et al.. (2010). Supporting cancer patients and their carers: the contribution of art therapy and clinical psychology. International Journal of Palliative Nursing. 15(12). 609–614. 1 indexed citations
4.
Peyton, James D., David R. Spigel, Howard A. Burris, et al.. (2009). Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: Preliminary results. Journal of Clinical Oncology. 27(15_suppl). 9027–9027. 9 indexed citations
5.
Moran, Mollie E., et al.. (2007). Nursing Guidelines for Managing Infections in Patients With Chronic Lymphocytic Leukemia. Clinical journal of oncology nursing. 11(6). 914–924. 3 indexed citations
6.
Ferrajoli, Alessandra, William G. Wierda, Ruth LaPushin, et al.. (2007). Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia. European Journal Of Haematology. 80(4). 296–298. 6 indexed citations
7.
Tam, Constantine S., Susan O’Brien, Susan Lerner, et al.. (2007). The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leukemia & lymphoma. 48(10). 1931–1939. 72 indexed citations
8.
Borthakur, Gautam, Stefan Faderl, Alessandra Ferrajoli, et al.. (2007). Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapies. Cancer. 110(11). 2478–2483. 7 indexed citations
9.
Wierda, William G., Susan O’Brien, Alessandra Ferrajoli, et al.. (2007). Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.. Blood. 110(11). 628–628. 24 indexed citations
10.
Tibes, Raoul, Michael J. Keating, Alessandra Ferrajoli, et al.. (2006). Activity of alemtuzumab in patients with CD52‐positive acute leukemia. Cancer. 106(12). 2645–2651. 66 indexed citations
11.
12.
Wierda, William G., Thomas J. Kipps, Michael J. Keating, et al.. (2006). Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.. Blood. 108(11). 2839–2839. 5 indexed citations
13.
Faderl, Stefan, Alessandra Ferrajoli, William G. Wierda, et al.. (2005). Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood. 106(11). 2963–2963. 11 indexed citations
14.
O’Brien, Susan, William G. Wierda, Stefan Faderl, et al.. (2005). FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL).. Blood. 106(11). 2117–2117. 19 indexed citations
15.
Faderl, Stefan, R. Kanti, John G. Gribben, et al.. (2004). Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.. Blood. 104(11). 4841–4841. 5 indexed citations
16.
O’Brien, Susan, Hagop M. Kantarjian, Deborah A. Thomas, et al.. (2003). Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 98(12). 2657–2663. 179 indexed citations
17.
Browning, Mary, et al.. (1971). Micronesian Heritage. Ethnomusicology. 15(2). 292–292. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mt Fierro Breakdown of academic impact, for papers by Amy Goodrich Breakdown of academic impact, for papers by R. F. Bezares Breakdown of academic impact, for papers by S Cardona Breakdown of academic impact, for papers by A. Lakhani Breakdown of academic impact, for papers by P Travade Breakdown of academic impact, for papers by K. R. Breakdown of academic impact, for papers by Jay Schachner Breakdown of academic impact, for papers by M. P. A. Lyttelton Breakdown of academic impact, for papers by M. Hidajat
Rankless by CCL
2026